Fortress Biotech Inc
NASDAQ:FBIO
Intrinsic Value
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. [ Read More ]
The intrinsic value of one
FBIO
stock under the Base Case scenario is
28.33
USD.
Compared to the current market price of 1.81 USD,
Fortress Biotech Inc
is
Undervalued by 94%.
Fortress Biotech Inc's market capitalization is 34.8m USD.
FBIO stock price is 1.81 USD.
FBIO stock price (1.81 USD) is 94% less than its Intrinsic Value (28.33 USD).
FBIO. Open DCF Valuation
FBIO stock price (1.81 USD) is 94% less than its Relative Value (28.33 USD). Open Relative Valuation
FBIO.
FBIO's Revenue has grown by 12% over the past 12 months.
FBIO's long-term assets (168m USD) exceed its long-term liabilties (145m USD).
FBIO's short-term assets (117m USD) exceed its short-term liabilties (85m USD).
FBIO has negative Net Debt. This means that the company has more cash and short-term investments (81m USD) than debt (61m USD).
FBIO's Revenue has been growing by an exceptional 23% per year for the last 3 years.
FBIO's Revenue is forecast to grow at a rate of 29% per year over the next 3 years.
FBIO's ROE (Return on Equity) has significantly decreased in the last 3 years from -60% to -214%, and is approaching profitability.
FBIO's ROIC (Return on Invested Capital) has significantly decreased in the last 3 years from -131% to -386%, and is approaching profitability.
FBIO has negative Operating Income for the last twelve months.
FBIO has negative Net Income for the last twelve months.
FBIO's ROE (Return on Equity) for the past 12 months is negative and is equal to -214%.
FBIO's ROIC (Return on Invested Capital) for the past 12 months is negative and is equal to -386%.
FBIO's D/E (Debt to Equity) is very high and is equal to 2.7.
FBIO has positive Gross Profit for the last twelve months.
FBIO has negative Free Cash Flow for the last twelve months.
FBIO has negative three-year average ROE (Return on Equity): -114%. The company is not efficient at transforming stockholders' equity into net income.
FBIO has negative three-year average ROIC (Return on Invested Capital): -366%. The company is not efficient at using invested capital to generate operating income.
FBIO's Altman Z-Score is very low and is equal to -8.16.
FBIO doesn't generate enough operating income (-139m USD) to safely cover interest payments on its debt (8m USD).
Fundamental Analysis
Fortress Biotech Inc
Balance Sheet Decomposition
Fortress Biotech Inc
| Current Assets | 117m |
| Cash & Short-Term Investments | 80.9m |
| Receivables | 15.4m |
| Other Current Assets | 20.7m |
| Non-Current Assets | 50.5m |
| PP&E | 23.5m |
| Intangibles | 20.3m |
| Other Non-Current Assets | 6.7m |
| Current Liabilities | 84.9m |
| Accounts Payable | 53m |
| Accrued Liabilities | 23.1m |
| Other Current Liabilities | 8.8m |
| Non-Current Liabilities | 60.1m |
| Long-Term Debt | 60.9m |
| Other Non-Current Liabilities | -782k |
Earnings Waterfall
Fortress Biotech Inc
|
Revenue
|
84.5m
USD
|
|
Cost of Revenue
|
-26.7m
USD
|
|
Gross Profit
|
57.9m
USD
|
|
Operating Expenses
|
-197.1m
USD
|
|
Operating Income
|
-139.2m
USD
|
|
Other Expenses
|
70.6m
USD
|
|
Net Income
|
-68.7m
USD
|
Free Cash Flow Analysis
Fortress Biotech Inc
What is Free Cash Flow?
FBIO Profitability Score
Profitability Due Diligence
Fortress Biotech Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
Score
Fortress Biotech Inc's profitability score is 24/100. The higher the profitability score, the more profitable the company is.
FBIO Solvency Score
Solvency Due Diligence
Fortress Biotech Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Score
Fortress Biotech Inc's solvency score is 27/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
FBIO Price Targets Summary
Fortress Biotech Inc
Ownership
FBIO Insider Trading
Buy and sell transactions by insiders
| Period | Sold | Bought | Net |
|---|---|---|---|
| 3 Months |
|
|
|
| 6 Months |
|
|
|
| 9 Months |
|
|
|
| 12 Months |
|
|
|
Shareholder Return
FBIO Price
Fortress Biotech Inc
| Average Annual Return | -6.92% |
| Standard Deviation of Annual Returns | 52.35% |
| Max Drawdown | -98% |
| Market Capitalization | 34.8m USD |
| Shares Outstanding | 19 234 500 |
| Percentage of Shares Shorted | 13.01% |
Company Profile
Fortress Biotech Inc
Country
Industry
Market Cap
Dividend Yield
Description
Fortress Biotech, Inc. engages in the manufacture and commercialization of novel pharmaceutical products and product candidates. The company is headquartered in Bay Harbor Islands, Florida and currently employs 173 full-time employees. The company went IPO on 2011-11-17. Fortress has seven marketed prescription pharmaceutical products and over 25 programs in development at Fortress, and at its partner companies. Its product candidates span six market areas, including oncology, rare diseases and gene therapy. The firm's commercialized products include Ximino, Targadox, Exelderm, Ceracade, Luxamend and Accutane. Its late-stage product candidates include Intravenous (IV) Tramadol, CUTX-101, MB-107 and MB-207, Cosibelimab, CK-101, CAEL-101, Triplex and CEVA101. Its product candidates also consist of MB-102 (CD123 CAR T for BPDCN), MB-101 (IL13Ra2 CAR T for Glioblastoma), MB-104, MB-106, MB-103, AVTS-001, CK-103 and ConVax. The firm operates in two operating and reportable segments: Dermatology Product Sales, and Pharmaceutical and Biotechnology Product Development.
You don't have any saved screeners yet
